scholarly journals Evaluation of complex treatment of patients with postoperative hypothyroidism and non-alcoholic fatty liver disease

2020 ◽  
pp. 20-20
Author(s):  
V.E. Gavrylenko
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Levothyroxine Sodium ◽  
Control Group ◽  
Comprehensive Treatment ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Objective. To evaluate the effectiveness of comprehensive treatment of patients with postoperative hypothyroidism (PH) and non-alcoholic fatty liver disease (NAFLD). Materials and methods. 40 patients (20 men and 20 women) aged 42±6 years with PH and NAFLD were examined. Patients were divided into two groups: main (n=20) and control (n=20). Prior to the study and after 1 month, the level of total cholesterol (TH), triglycerides (TG), low-density lipoprotein (LDL), alanine aminotransferase (ALT), aspartate aminotransferase (AST) was determined. Patients in both groups were prescribed levothyroxine sodium (125-175 μg a day). Additionally, the 1st group of patients received arginine hydrochloride 42 mg/ml according to the scheme 200 ml a day per 15 days, the next 15 days L-arginine aspartate 200 mg/ml 5 ml a day. And the control group received only levothyroxine sodium. Results. The level of TH in 1st group decreased from 7.1±0.8 to 6.7±0.4 mmol/l, and in 2nd – from 7.2±0.7 to 6.97±0.35 mmol/l. In the 1st group TG decreased from 3.9±0.4 to 3.5±0.3 mmol/l, and in the 2nd – from 3.8±0.5 to 3.7±0.1 mmol/l. LDL in 1st group decreased from 5.9±1.4 to 5.5±1.2 mmol/l, in the 2nd – from 5.8±1.3 to 5.7±1.4 mmol/l. The level of ALT in 1st group decreased from 47.5±1.82 to 40.1±1.73 IU/l, the level of AST – from 41.3±1.52 to 39.8±1.33 IU/l, in no changes in AST and ALT levels were observed in the control group. Conclusions. Comprehensive treatment of patients with PH and NAFLD contributed to the improvement of liver transaminases (reduction of AST, ALT), as well as the normalization of the lipid profile (reduction of TC, TG and LDL).

scholarly journals Lipid Profile in Alcoholic and Non Alcoholic Fatty Liver Patients

2020 ◽  
Author(s):  
Aakash Shahi ◽  
Narayan Gautam ◽  
Sanju Rawal ◽  
Uday Sharma ◽  
Archana Jayan
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Lipid Profile ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
P Value ◽  
Alcoholic Fatty Liver ◽  
Significant Difference ◽  
Alcoholic Fatty Liver Disease

Abstract Background: Fatty liver disease is a common and major chronic liver disease. It has been implicated that patients have disorders of lipid metabolism and involved in the pathogenesis of fatty liver. Lipid profile plays a very important role in diagnosis of liver diseases hence it was designed to observe relationship between lipid profile and fatty liver disease (FLD) based on ultrasonography (USG).Method and methodology: This Cross-sectional and analytical study was undertaken in the Department of Internal Medicine with collaboration of Department of Radiology and Department of Biochemistry, Universal College of Medical Sciences-Teaching Hospital (UCMS-TH), Bhairahawa, Nepal from March 2019 to February 2020 in total 100 patients diagnosed with FLD by USG.Result: In 100 cases, the male to female ratio was 1.8:1. 56% of the total cases presented with alcoholic fatty liver disease (AFLD) while remaining 44% with non alcoholic fatty liver disease (NAFLD). The spectrum of lipid abnormality was observed with increased total cholesterol (TC), Low Density Lipoprotein (LDL), increased triglycerides (TG) and Very Low Density Lipoprotein (VLDL) in AFLD cases as compared to NAFLD cases. However, it has been observed that TG/HDL and Non-HDL/HDL were higher in NAFLD as compared to AFLD. There was statistical significant difference in HDL (p-value: 0.019) between alcoholic fatty liver disease grade 1 (AFLG1) and non-alcoholic fatty liver disease grade 1 (NAFLG1). Moreover, it was observed statistical significant difference in HDL between AFLG2 and NAFLG2 (p-value: 0.012).Conclusion:Elevated level of TG and decreased HDL has been implicated in the precipitation of the occlusive vascular disease. These parameters in conjunction with Non-HDL/HDL and TG/HDL can be useful in early screening and monitoring of dyslipidemia in the fatty liver patients to prevent cardiovascular diseases.

scholarly journals Hypolipidemic therapy in patients with non-alcoholic fatty liver disease

2010 ◽  
Vol 1 (1) ◽  
pp. 38-45
Author(s):  
L. B Lazebnik ◽  
L. A Zvenigorodskaya ◽  
N. G Samsonova ◽  
E. A Cherkasova ◽  
N. V Melnikova
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cholesterol Absorption ◽  
Atherogenic Dyslipidemia ◽  
Cardiovascular Risks ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Dyslipidemia is currently accepted to be one of the major risk factor for cardiovascular diseases and atherosclerosis. There is no question that the liver plays an important role in the development of atherogenic dyslipidemia and it is simultaneously a target organ, which results in the development of non-alcoholic fatty liver disease (NAFLD). The latter limits the feasibilities of adequate hypolipidemic therapy, thus increasing the cardiovascular risks. There is a need to use hepatoprotectors when atherogenic dyslipidemia in a patient with documented NAFLD is treated with statins and fibrates. The choice of hepatoprotectors depends on the stage of NAFLD. It is expedient to take statins in combination with ursodeoxycholic acid preparations in NAFLD at the stage of steatosis. A combination of statins and a cholesterol absorption inhibitor is more effective in achieving low-density lipoprotein cholesterol goals in patients with hypercholesterolemia. Intestinal microflora-normalizing agents (enteric antiseptics, pre- and probiotics) should be included into a complex of hypolipidemic therapy in patients with NAFLD. Key words: atherogenic dyslipidemia, non-alcoholic fatty liver disease, hypolipidemic therapy.

scholarly journals Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound

2016 ◽  
Vol 73 (10) ◽  
pp. 910-920 ◽  
Author(s):  
Gordana Petrovic ◽  
Goran Bjelakovic ◽  
Daniela Benedeto-Stojanov ◽  
Aleksandar Nagorni ◽  
Vesna Brzacki ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Density Lipoprotein ◽  
Control Group ◽  
Alcoholic Fatty Liver ◽  
Number Of Patients ◽  
Alcoholic Fatty Liver Disease

Introduction/ aim. Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease of a broad histological spectrum, characterized by the accumulation of triglycerides in more than 5% of hepatocytes in the absence of consuming alcohol in quantities harmful to the liver. The aim of our study was to determine the importance of anthropometric and laboratory parameters as well as metabolic syndrome (MS) for the diagnosis of NAFLD and to estimate their influence on the degree of liver steatosis as evaluated by ultrasound (US). Methods. The study included 86 participants, 55 of whom had fatty liver diagnosed by ultrasound and they comprised the study group. The control group consisted of 31 control subjects. During the course of hospitalization at the Clinic of Gastroenterology and Hepatology, Clinical Centre Nis, the patients had their anamnesis taken, and anthropometric measurements as well as biochemical blood analyses and abdominal ultrasound were performed. Results. The patients with NAFLD had statistically higher values of body mass index (BMI), waist circumference (WC), systolic (SBP) and diastolic blood pressure (DBP), levels of alanin and aspartate aminotransferase (ALT, AST), gamma-glutamyl transpeptidase (GGT) (p<0.001), low-density lipoprotein cholesterole (LDL), total bilirubin (TBIL) (p<0.05), total cholesterol (p<0.01), triglycerides (TGL), urates, C-reactive protein (CRP), ferritin, fibrinogenes, fasting blood glucose (FBG), insulin and Homeostasis Model Assessment (HOMA-IR) (p<0.001), whereas the levels of high-density lipoprotein cholesterol (HDL) were higher in the control group (p<0.05). In the NAFLD group, there were statistically significantly more patients with hypertension (72.73% vs. 12.90%, p<0.001) and type 2 diabetes mellitus (DM) (47.27%). Metabolic syndrome was determined in 48 (87.27%) patients of the study group. An equal number of patients, 16 of them (29.09%), had 3, 4 and 5 components of MS. In the NAFLD group there were 17 overweight (30.91%) (BMI from 25 kg/m2 to 29.9 kg/m2) and 38 (69.09%) obese patients. (BMI ? 30.0 kg/m2). The largest number of patients in the obesity group, 22 (40.00%) of them, had the first degree obesity (BMI from 30 kg/m2 to 34.99 kg/m2). The largest number of the NAFLD group patients - 23 (41.82%), had an ultrasound finding of grade 3 fatty liver, 20 patients (36.36%) had grade 2 and 12 (21.82%) grade 1 fatty liver. Kruskal-Wallis test and ANOVA analysis showed statistically significant differences between groups with different US grade for insulin, LDL-cholesterol, WC, BMI (p<0.05), as well as HOMA-IR and body weight (BW) (p<0.01). Metabolic syndrome was statistically more present in patients with US finding grades 2 and 3 (p<0.01) in relation to grade 1 US finding, as well as obesity, hypertension and DM type 2 (p<0.05). Conclusion. The results of our study have confirmed that a high percentage of patients with high risk factors (DM, MS, dyslipidemia, hypertension) have NAFLD.

scholarly journals Lipid profile in different grades of Ultrasonic Non-Alcoholic Fatty Liver Disease

2017 ◽  
Vol 13 (2) ◽  
pp. 258-261 ◽  
Author(s):  
Khem Raj Bhusal ◽  
Rabindra Simkhada ◽  
Pramod Nepal
Keyword(s):  
Liver Disease ◽  
High Density Lipoprotein ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
P Value ◽  
Low Density ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background & Objectives: This study was conducted with objective of studying the lipid abnormalities in patients with non-alcoholic fatty liver disease diagnosed on the basis of ultrasound.Materials & Methods: Total 100 patients consisting of 67 males and 37 females diagnosed as Non-alcoholic fatty liver disease on the basis of ultrasound were included in the study. Laboratory values of different lipid parameters were compared in different grades of these patients.Results: Out of total 100 cases, mild nonalcoholic fatty liver disease was found in 83 %, moderate in 17 % and severe in none of the participants. Age of the participants ranged from 26 to 79 years with mean being 45 ± 11.99 years. Presence of dyslipidemia was found in 94 % of the cases. Triglycerides, total cholesterol and low density lipoprotein levels were raised in 59, 53, 72% of the cases respectively and High density lipoprotein level was decreased in 57% of participants. There was significant positive correlation of presence of non-alcoholic fatty liver disease with increasing levels of serum total cholesterol (P value <0.001), low density lipoprotein (P value <0.001) and triglyceride (P value <0.001) and significantly decreasing high density lipoprotein (P value <0.001). Whereas increasing grades of non-alcoholic fatty liver disease weren’t significantly associated with increasing level of lipid abnormalities.Conclusion: This study showed the high prevalence of dyslipidemia in non-alcoholic fatty liver patients. Early detection with simple non-invasive ultrasonography is very useful to detect dyslipidemic patients.

Probiotic and prebiotic interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis

2021 ◽  
pp. 1-14
Author(s):  
H. Jin ◽  
X. Xu ◽  
B. Pang ◽  
R. Yang ◽  
H. Sun ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Randomised Trials ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Many studies have associated altered intestinal bacterial communities and non-alcoholic fatty liver disease, but the putative effects are inconclusive. The purpose of this network meta-analysis (NMA) was to evaluate the effects of probiotics, prebiotics, and synbiotics on non-alcoholic fatty liver disease through randomised intervention trials. Literature searches were performed until March 2020. For each outcome, a random NMA was performed, the surface under the cumulative ranking curve (SUCRA) was determined. A total of 22 randomised trials comparing prebiotic, probiotic, and synbiotic treatments included 1301 participants. Considering all seven results (aspartate aminotransferase, alanine aminotransferase, body mass index, weight, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) together, the highest SUCRA values are probiotics (94%), synbiotics (61%) and prebiotics (56%), respectively. NMA results provide evidence that probiotics, prebiotics, and synbiotics can alleviate non-alcoholic fatty liver disease. However, due to the lack of high-quality randomised trials, this research also has some limitations.

scholarly journals S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease

2015 ◽  
Vol 62 (3) ◽  
pp. 673-681 ◽  
Author(s):  
Maite Martínez-Uña ◽  
Marta Varela-Rey ◽  
Daniela Mestre ◽  
Larraitz Fernández-Ares ◽  
Olatz Fresnedo ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Hepatoprotective Effect of Leaves of Morinda tinctoria Roxb. Against Non-alcoholic Fatty Liver Disease in Rats

2021 ◽  
pp. 237-249
Author(s):  
Anil K. Yadav ◽  
Anoop Singh
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Uttar Pradesh ◽  
Aspartate Transaminase ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease ◽  
Morinda Tinctoria

Aim: To study the hepatoprotective and antioxidant activity of 50% aqueous-alcoholic leaves extract of Morinda tinctoria (Rubiaceae) against non-alcoholic fatty liver disease. Study Design: All experiments involving animals complies with the ethical standards of animal handling and approved by institutional animal ethical and welfare committee of the Institute of Pharmacy, PSIT (1273/AC/09/ CPCSEA) and plant were collected from Ranan Nagar, Madurai, Tamil Nadu, India and was authenticated by Dr. Navin K. Ambasht, Head and Associate Professor, Botany Department, Christ Church College, Kanpur, Uttar Pradesh, India. Place and Duration of Study: The study was carried out at Institute of Pharmacy, PSIT, Kanpur, Uttar Pradesh, India, during 2018-21. Methodology: The hepatoprotective potential of Morinda tinctoria leaves extract (MTLE) 150 and 300 mg/kg body weight was studied on Methionine and Choline deficient diet, High Fat Diet, Cholesterol and Cholate diet, and Streptozotocin + HFD induced non-alcoholic fatty liver disease. At the end of the treatment blood sample was collected from direct cardiac puncture and analysed for various parameter like alanine aminotransferase, aspartate transaminase, low density lipoprotein, high density lipoprotein, triglycerides, total cholesterol, free fatty acid and malondialdehyde. Results: The phytochemical investigation of extract showed presence of alkaloids, flavonoids, amino acid, saponin, tannins, phenols, carbohydrate and for the first time the present study showed that Morinda tinctoria leaves extract reduced level of alanine aminotransferase, aspartate transaminase, triglycerides, total cholesterol, low density lipoprotein, free fatty acid, malondialdehyde and enhance the level of Superoxide dismutase, High Density Lipoprotein and it also returned hepatic damage towards normal which further supports hepatoprotective and antioxidant activity of M. tinctoria. leaves extracts. Conclusions: M. tinctoria leaves extract showed maximum curation in the dose 300 mg/kg body weight against non-alcoholic fatty liver disease.

Sign in / Sign up

Export Citation Format

Share Document